P Starlinger1, D S Ubl2, H Hackl3, J Starlinger4, D M Nagorney1, R L Smoot1, E B Habermann2, S P Cleary1. 1. Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA. 2. Mayo Clinic Robert D and Patricia E Kern Center for the Science of Health Care Delivery and Department of Health Services Research, Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. 4. 37binary UG, Berlin, Germany.
Abstract
BACKGROUND: Aspartate aminotransferase/platelet ratio index (APRI) and albumin-bilirubin grade (ALBI) are validated prognostic indices implicated as predictors of postoperative liver dysfunction after hepatic resection. The aim of this study was to evaluate the relevance of the combined APRI/ALBI score for postoperative clinically meaningful outcomes. METHODS: Patients undergoing hepatectomy were included from the American College of Surgeons National Surgical Quality Improvement Program database. The association between APRI/ALBI score and postoperative grade C liver dysfunction, liver dysfunction-associated and overall 30-day mortality was assessed. RESULTS: A total of 12 055 patients undergoing hepatic resection from 2014 to 2017 with preoperative blood values and detailed 30-day postoperative outcomes were included (exploration cohort: January 2014 to December 2016; validation cohort: 2017). In the exploration cohort (8538 patients), the combination of both scores (APRI/ALBI) was significantly associated with postoperative grade C liver dysfunction, 30-day mortality, and liver dysfunction-associated 30-day mortality, and was superior to either score alone. The association with postoperative 30-day mortality was confirmed in multivariable analysis. A predictive model was generated using the exploration cohort. The predicted incidence of events closely followed the observed incidence in the validation cohort (3517 patients). Subgroup analyses of tumour types were used to generate disease-specific risk models to assess risk in different clinical scenarios. These findings informed development of a smartphone application (https://tellaprialbi.37binary.com). CONCLUSION: The predictive potential of the combined APRI/ALBI score for clinically relevant outcomes such as mortality was demonstrated. An evidence-based smartphone application will allow clinical translation and facilitation of risk assessment before hepatic resection using routine laboratory parameters.
BACKGROUND: Aspartate aminotransferase/platelet ratio index (APRI) and albumin-bilirubin grade (ALBI) are validated prognostic indices implicated as predictors of postoperative liver dysfunction after hepatic resection. The aim of this study was to evaluate the relevance of the combined APRI/ALBI score for postoperative clinically meaningful outcomes. METHODS: Patients undergoing hepatectomy were included from the American College of Surgeons National Surgical Quality Improvement Program database. The association between APRI/ALBI score and postoperative grade C liver dysfunction, liver dysfunction-associated and overall 30-day mortality was assessed. RESULTS: A total of 12 055 patients undergoing hepatic resection from 2014 to 2017 with preoperative blood values and detailed 30-day postoperative outcomes were included (exploration cohort: January 2014 to December 2016; validation cohort: 2017). In the exploration cohort (8538 patients), the combination of both scores (APRI/ALBI) was significantly associated with postoperative grade C liver dysfunction, 30-day mortality, and liver dysfunction-associated 30-day mortality, and was superior to either score alone. The association with postoperative 30-day mortality was confirmed in multivariable analysis. A predictive model was generated using the exploration cohort. The predicted incidence of events closely followed the observed incidence in the validation cohort (3517 patients). Subgroup analyses of tumour types were used to generate disease-specific risk models to assess risk in different clinical scenarios. These findings informed development of a smartphone application (https://tellaprialbi.37binary.com). CONCLUSION: The predictive potential of the combined APRI/ALBI score for clinically relevant outcomes such as mortality was demonstrated. An evidence-based smartphone application will allow clinical translation and facilitation of risk assessment before hepatic resection using routine laboratory parameters.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Jean-Nicolas Vauthey; Timothy M Pawlik; Dario Ribero; Tsung-Teh Wu; Daria Zorzi; Paulo M Hoff; Henry Q Xiong; Cathy Eng; Gregory Y Lauwers; Mari Mino-Kenudson; Mauro Risio; Andrea Muratore; Lorenzo Capussotti; Steven A Curley; Eddie K Abdalla Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Luca Vigano; Giovanni De Rosa; Christian Toso; Axel Andres; Alessandro Ferrero; Arnaud Roth; Elisa Sperti; Pietro Majno; Laura Rubbia-Brandt Journal: J Hepatol Date: 2017-03-09 Impact factor: 25.083
Authors: Ye Xin Koh; Hiang Jin Tan; Yi Xin Liew; Nicholas Syn; Jin Yao Teo; Ser Yee Lee; Brian K P Goh; George B B Goh; Chung Yip Chan Journal: J Am Coll Surg Date: 2019-08-06 Impact factor: 6.113
Authors: Srinevas K Reddy; J Wallis Marsh; Patrick R Varley; Brady K Mock; Kapil B Chopra; David A Geller; Allan Tsung Journal: Hepatology Date: 2012-10-14 Impact factor: 17.425
Authors: D J Pinato; C Yen; D Bettinger; R Ramaswami; T Arizumi; C Ward; M Pirisi; M E Burlone; R Thimme; M Kudo; R Sharma Journal: Aliment Pharmacol Ther Date: 2017-01-24 Impact factor: 8.171
Authors: Ramsey C Cheung; Sue Currie; Hui Shen; Edmund J Bini; Samuel B Ho; Bhupinderjit S Anand; Ke-Qin Hu; Teresa L Wright; Timothy R Morgan Journal: J Clin Gastroenterol Date: 2008-08 Impact factor: 3.062